ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Aligos Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$4.84−0.02 (-0.41%)

Close on Oct 19, 2026

Market cap: $50.49M
P/E (TTM): –
Dividend yield: –

Aligos Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Stock-Based Compensation	5.04	8.45	13	15	13	2.98	0.75
Deferred Income Taxes	–	0	0	0	0	0	0
Change in Accounts Payable	1.41	0.05	-2.22	1.72	-0.31	-0.13	0.39
Change in Unearned Revenue	-0.15	-1.16	-8.14	2.50	-4.36	12	–
Operating Cash Flow	-83	-81	-79	-79	-116	-74	-47
Capital Expenditures	–	-0.13	-0.02	-0.94	-0.89	-2.06	-2.79
Purchase of Investments	-165	-108	-0.01	-104	-19	-45	-70
Investing Cash Flow	-38	-18	45	-26	3.02	33	6.79
Stock Issued	–	–	0.02	–	–	–	–
Financing Cash Flow	102	0.36	88	0.16	79	192	86
Free Cash Flow	–	-81	-79	-80	-117	-76	-50
Income Taxes Paid	0.32	–	–	–	–	–	0.00
Interest Paid	–	–	–	–	–	–	0.01

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -2112.1%
Net margin: -2031.1%
Return on equity, FY2025: -196.9%

Financial strength

Current ratio: 2.19
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 107.2%

Valuation

P/E ratio: –
Price to sales: 13.50
Price to book: 1.58
Dividend yield: –